GlaxoSmithKline plc and the German CureVac AG will develop a vaccine, including, against the new COVID-19 types Koronavirus

The British company GlaxoSmithKline plc and the German firm of CureVac AG on Wednesday declared plans to combine efforts in development vaccines from Koronavirus which will work and against new strains of this virus. "In February, 2021 we declared that we will cooperate with CureVac AG over joint development the following generation of a RNA vaccine from Koronavirus with a potential concerning various arisen options (a virus - IF)", - is spoken in GSK statement. At this GSK will render CureVac AG help in production 100 million doses of a vaccine of the first generation against Koronavirus ". We believe that vaccines...